Plasma expression of HIF-1α as novel biomarker for the diagnosis of obstructive sleep apnea-hypopnea syndrome

血浆中HIF-1α的表达可作为阻塞性睡眠呼吸暂停低通气综合征诊断的新型生物标志物

阅读:3
作者:Caidong Liu,Haoyu Wang,Chenbin Zhu,Shukui Wang

Abstract

Background: Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a common breathing disorder during sleep with potential lethality and multi-complications. Polysomnography (PSG) is now the golden standard for the diagnosis obstructive sleep apnea-hypopnea syndrome. However, PSG is expensive and time-consuming. Therefore, it is important to find inexpensive and convenient biomarkers for the diagnosis of OSAHS. Objective: The present study aimed to explore the potential diagnostic value of HIF-1α for OSAHS and its clinical significance. Methods: This study consisted of 368 patients admitted to the sleep laboratory. The patients were classified according to their apnea-hypopnea index (AHI) scores as OSA negative (AHI < 5), mild-moderate (AHI:5-30), and severe OSA (AHI > 30), and severe OSA treated with continuous positive airway pressure (CPAP). qRT-PCR was used to detect mRNA levels in the plasma; Pearson's correlation analysis was performed to analyze the correlation of HIF-1α mRNA level and the clinicopathological factors of OSAHS; ROC curve was constructed to evaluate the diagnostic value of HIF-1α mRNA. Results: HIF-1α mRNA was significantly up-regulated in the plasma of OSAHS patients, especially patients with severe OSAHS. HIF-1α mRNA was positively correlated with the AHI and ODI but negatively correlated with the mean oxygen saturation in patients with OSAHS. Results of ROC curve showed that HIF-1α is a sensitive biomarker for the diagnosis of OSAHS, especially severe OSAHS. Conclusions: HIF-1α mRNA might be used as s a convenient and inexpensive method for triaging OSAHS patients PSG assessment in the hospital and evaluate the curative effect.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。